Sponsor content
213 result(s) found, displaying 81 to 90
-
Cancellation by sponsorRequested by Roche Products Pty Ltd
-
Cancellation by sponsorRequested by Roche Products Pty Ltd
-
-
-
Prescription medicine registrationActive ingredients: baloxavir marboxil.
-
Prescription medicine registrationActive ingredients: pertuzumab; trastuzumab.
-
Roche Products Pty Ltd - Medicine administration kit, oral ancelled under Section 41GL(d) of the Act
Cancellation by sponsorRequested by Roche Products Pty Ltd -
Cancellation by sponsorRequested by Roche Products Pty Ltd
-
Australian public assessment report (AusPar)Australian Public Assessment Report for Entrectinib
-
Prescription medicine decision summaryTGA decision: ENSPRYNG (satralizumab) is approved to treat adults with neuromyelitis optica spectrum disorders who have an AQP4-IgG.